Appendix D

**National Action Plan development support tools**

**Sample Checklist**

*This checklist was developed to be used by multidisciplinary teams in countries to assist with the development of their national action plan (NAP) on AMR or assist with reviewing and updating existing national action plans.*

**Existing National Action Plan**

*\*\*If there is no National Action Plan please SKIP Questions 1-4 and go directly to Question 5*

|  |  |
| --- | --- |
| 1. **There is already a national action plan (NAP) on AMR** | ☑=Y |
| * 1. **The plan is based on a national strategy on AMR.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The plan is officially approved by the government and published with open access.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **A dedicated budget is allocated for implementing the activities in the plan.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The plan is aligned to a national health plan and other human, animal, plant and environmental health strategies and food safety strategies** e.g. infection prevention and control, patient safety, environmental health, animal health and welfare,plant production, regulation of use of antimicrobial agents | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The plan is updated regularly.** e.g. within at least 5 years | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **A national AMR progress report on implementation of the NAP is published regularly with open access.** e.g. within at least 5 years | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |  |
| --- | --- | --- |
| 1. **The national action plan reflects the principles outlined in the global action plan.**   **\*\*If there is no National Action Plan please SKIP Questions 1-4 and go directly to Question 5** | | ☑=Y |
| * 1. **Whole-of-society engagement** including a “one health” approach: all sectors in addition to human health (e.g. animal health, plants, food, environment, economic development, education) should be engaged in the preparation and implementation of the action plan. | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Prevention first** Prevention of infection can be cost-effective and implemented in all settings and sectors, even where resources are limited. | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Access** Both equitable access to and appropriate use of existing and new antimicrobial agents are required. | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Sustainability** Long-term technical and financial investment is needed for implementation of the national plan. | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Incremental targets** The plan will be implemented in a stepwise manner to meet both local needs and global priorities | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Meets intergovernmental standards where relevant**   e.g. Codex, OIE Code | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | | |

|  |  |
| --- | --- |
| 1. **The national action plan addresses the five strategic objectives of the global action plan** | ☑=Y |
| * 1. **Strategic objective 1** Improve awareness and understanding of AMR through effective communication, education and training. | **⭘** Done  **⭘**  In progress  **⭘** Not done |
| * 1. **Strategic objective 2** Strengthen the knowledge and evidence base through surveillance and research. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Strategic objective 3** Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Strategic objective 4** Optimize the use of antimicrobial agents in human, animal and plant health. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Strategic objective 5** Develop the economic case for sustainable investment, taking into account the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **The national action plan includes key components of a comprehensive plan.** | ☑=Y |
| * 1. **Strategic (core) plan** Explains and specifies goals, objectives and strategic interventions that match the situation analysis and linked to the global action plan strategic objectives. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Operational plan (including technical assistance planning)** Provides detailed information on each activity and milestone for the coming 1 or 2 years of the period covered by the plan | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Monitoring and evaluation plan** Refers to each operational objective and each strategic intervention defined in the core plan and includes indicators to assess achievement against a baseline and data collection method | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Budget plan** Establishes the costs of each activity in each year of the plan and identifies both funding and funding gaps for each year and for the overall period covered by the plan | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

**Governance and multisectoral “One Health” coordination**

|  |  |
| --- | --- |
| 1. **There is national coordination on activities in the country among AMR focal points, with defined roles and responsibilities, including to:** | ☑=Y |
| * 1. **Facilitate formation of a national multisectoral coordinating group (NMCG)** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Facilitate and coordinate development of the national AMR action plan through the NMCG.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Facilitate and oversee implementation, monitoring and evaluation of the AMR action plan through the NMCG.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Ensure regular data collection and information-sharing among all relevant sectors and stakeholders** by facilitating effective communication and coordination between the members of the NMCG and with international partners | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **A national multisectoral coordinating group (NMCG) is established.** | ☑=Y |
| * 1. **The NMCG has strong political support.** ideally, created by regulation and overseen by the prime minister’s office or equivalent to ensure inter-Ministry cooperation | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The NMCG has authority to act.** Sufficient authority is assigned to enable NMCG recommendations and plans to be implemented. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The NMCG is accountable to the government.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The NMCG has dedicated funds.** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The NMCG has a secretariat** with dedicated personnel and funds for administrative costs. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The NMCG is supported by technical experts**   including human and animal health, plant, food, and environmental expertise. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **The national multisectoral coordinating group (NMCG) ensures ownership of activities in multiple sectors and considers the perspectives of the following bodies and institutes at national and subnational levels[[1]](#footnote-1) (please adapt this list to your country’s situation)** | ☑=Y |
| * **Ministries**   e.g. those responsible for human health, animal health, plant production, food safety , education, commerce | 🗆 |
| * **Regulatory authorities**   e.g. for medicines, agricultural products | 🗆 |
| * **Public agencies**   e.g. hospital authorities, epidemiology units, surveillance units, veterinary services, veterinary statutory bodies | 🗆 |
| * **Laboratories**   e.g. human health, animal health, plant health, food, water, sewage, environment etc.  e.g. public, private, academic | 🗆 |
| * **Universities, academic, and research institutions** | 🗆 |
| * **Private sector**   e.g. animal production and food processing industries, private hospitals, private veterinary associations, farmers associations, pharmaceutical industry, health insurance | 🗆 |
| * **Civil society**   e.g. patient groups, sectoral professional bodies, medical associations | 🗆 |
| * **Others** | 🗆 |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **Technical working groups are created as needed. Members may represent the following areas[[2]](#footnote-2) (please adapt this list to your country’s situation).** | ☑=Y |
| * **Human health** | 🗆 |
| * **Animal health, welfare, and production including fisheries** | 🗆 |
| * **Food safety and security, including food production and processing** | 🗆 |
| * **Plants and agriculture** | 🗆 |
| * **Environment, including water and sewage** | 🗆 |
| * **Technical disciplines**   e.g. Infectious diseases, pharmacy, IPC, epidemiology, | 🗆 |
| * **Others** |  |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **Guidance, tools, data and case studies are available to form a basis for preparation of a national action plan on AMR.** | ☑=Y |
| * 1. **Stakeholder mapping and analysis** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Review of existing tools and projects** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Situational analyses**   e.g. Drivers of AMR in the country, availability of antimicrobial use data | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Gap analysis and needs assessment** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Determining strategic priorities, objectives, interventions, activities** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Drafting key documents** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Validation of key documents** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Implementation, monitoring and evaluation** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

**GAP Strategic Objective 1.** Improving awareness and understanding of antimicrobial resistance through effective communication, education and training

|  |  |
| --- | --- |
| 1. **Activities to increase national awareness of AMR are planned, including:** | ☑=Y |
| * 1. **Public communication programmes targeting audiences in human health practice** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Public communication programmes targeting audiences in animal health practice** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Public communication programmes targeting audiences in plant production and crops** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Public communication programmes targeting audiences along the food chain** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Public communication programmes targeting audiences in the environmental sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Country participates in an annual world or regional AMR awareness campaign** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1. **AMR and related topics are core (mandatory) components of education, training, and development** | | | | | |
|  | Human health | Animal health | Plant production | Food chain | Environment |
| * 1. **AMR and related topics included in undergraduate curricula** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR and related topics included in continuing education programmes** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR and related topics included in quality assurance programmes?** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR and related topics included in education/training provided outside formal academic settings** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | | | | | |

|  |  |
| --- | --- |
| 1. **Education and information on AMR provided to the general public.** | ☑=Y |
| * 1. **Include antimicrobial use and resistance in school curricula** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Provide accurate, relevant information on AMR to public** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **AMR is recognized as a national priority.** | ☑=Y |
| * 1. **Use effective mechanisms to ensure inter-ministerial collaboration and commitment** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Promote and support establishment of public-private, multisectoral (“One Health”) coalitions to address AMR at local or national level** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Promote and support participation in public-private, multisectoral (“One Health”) coalitions to address AMR at regional and global level** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

**GAP Strategic Objective 2.** Strengthen the knowledge and evidence base through surveillance and research.

|  |  |
| --- | --- |
| 1. **National AMR surveillance and use monitoring systems exist or are planned, comprising:** | ☑=Y |
| * 1. **Surveillance of AMR in isolates from humans** e.g. in health care facilities and the community | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Surveillance of AMR in isolates from animals** e.g. livestock, aquatic animals, companion animals | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Surveillance of AMR in isolates from food** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Surveillance of AMR in isolates from plants** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Surveillance of AMR in isolates from the environment** e.g. sewage, water | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Monitoring of use of antimicrobial agents in humans** e.g. in health care facilities and the community | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Monitoring of use of antimicrobial agents in animals** (including the OIE collection of data) | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Monitoring of the use of antimicrobial agents in plants** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Special studies to provide information not covered by routine surveillance** to provide supplementary information on, for example, AMR burden, effects of interventions, potential causes and drivers of AMR emergence, AMR in wildlife | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |
| 1. **Data on the extent and impact of AMR are available** | ☑=Y |
| * 1. **Incidence and prevalence of AMR in humans, animals, plants, food, and environment** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Human morbidity, mortality and other health outcomes in relation to AMR** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Data on economic impact of AMR in humans, animals, plants, food, and the environment** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **A national AMR surveillance and antimicrobial use (AMU) report (within the past 5 years) publicly available, including** | ☑=Y |
| * 1. **AMR in isolates from humans** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR in isolates from animals** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR in isolates from plants** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR in isolates from food** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **AMR in isolates from the environment** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Antimicrobial use in humans** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Antimicrobial use in animals** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Antimicrobial use in plants** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **A national mechanism coordinates the different national AMR surveillance and antimicrobial use (AMU) monitoring systems** | ☑=Y |
| * 1. **Defines the objectives of the national surveillance systems based on intergovernmental standards** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Reviews and coordinates dissemination of existing national AMR surveillance and AMU monitoring protocols (and coordinates protocol development as needed)** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Coordinates AMR data collection, analysis, reporting and sharing across the human health, animal health, food, plant and environmental sectors**   both nationally and with international and global networks | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Monitors data on the use of antimicrobial agents in humans, animals, and plants, and continuously evaluates the national surveillance systems** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Links and coordinates AMR surveillance in the human health, animal health, plant, food, and environment sectors** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **One or more national reference laboratories have been nominated for surveillance of AMR, to** | ☑=Y |
| * 1. **Accurately confirm diagnoses** including verification of results (detection or confirmation of unusual or new resistance patterns) reported by participating laboratories, detection of specific microbial markers and investigation of atypical samples | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Develop, maintain and share relevant reference material** including reference laboratory strains and cultures, clinical isolates, sera, genetic material. | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Serve as a resource and coordination point for expertise and for sharing information and advice with relevant stakeholders** including technical advice on methods and procedures, scientific support and advice on the interpretation and relevance of laboratory findings | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Engage in collaboration and research** including participation in and contribution to international and global surveillance and internationally relevant projects and initiatives, including research and development activities | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Provide guidance and technical support for the management of quality, including participation in external quality assurance schemes** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Liaise with the national AMR coordinating mechanism** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **A national research agenda implemented, including** | ☑=Y |
| * 1. **Social science and behavioural studies and other research to support achievement of the global objectives** including studies to promote responsible use of antimicrobial agents and effective antimicrobial stewardship programmes in human health, animal health, and plant health | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Research to develop new treatments, diagnostic tools, vaccines and other interventions in humans, animal, and plants related to infectious diseases**   involving promotion of partnerships between research institutions at national, regional and international level | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Research to identify alternatives to non-therapeutic uses of antimicrobial agents in animals and plants** including their use for growth promotion and crop protection | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Economic research, including development of models to assess the cost of AMR and the costs and benefits of the national action plan for the human health, animal health, food, plant and environment sectors** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

**GAP Strategic Objective 3.** Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.

|  |  |
| --- | --- |
| 1. **Infection prevention and control (IPC) programmes introduced across the spectrum of human health settings, including** | ☑=Y |
| * 1. **A national programme for IPC in health care** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **IPC programmes in hospitals** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **IPC programmes in long-term care and outpatient and community health settings** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **IPC programmes in congregate settings**   e.g. correctional facilities and military barracks, to homeless shelters, refugee camps, dormitories and nursing homes | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **Intergovernmental standards and guidelines related to infection prevention and control (IPC) implemented in** | ☑=Y |
| * 1. **The animal health sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The plant sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The food sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **The environment sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **The infection prevention and control (IPC) programmes for human health adapted to local conditions and include the following essential (core) components:** | ☑=Y |
| * 1. **A formal organizational structure to facilitate proper development and management of IPC policies and strategies** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Infection control guidelines and policies, including strategies and guidelines for AMR** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Training of health care providers in the principles and practice of IPC** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Appropriate environment (including facilities and environmental designs) for application of IPC principles and practices** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Laboratory and diagnostic support for prescribing antimicrobial agents and accurate, timely detection of infections caused by resistant pathogens** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Surveillance systems**   to collect and report data on health care-associated infections and the susceptibility of the microorganisms to antimicrobial agents to enable rapid detection and containment of emerging drug-resistant microorganisms | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Monitoring and evaluation framework to monitor implementation and enable timely adaptation of IPC strategies** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Links with public health, other services and societal bodies to facilitate communication** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 1. **Training and education in hygiene and IPC are core (mandatory) components of education, training, and development** | | | | |  | |
|  | Human health | Animal health | Plant production | Food chain | | Environment | |
| * 1. **Hygiene and IPC included in undergraduate curricula** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Hygiene and IPC included in continuing education programmes** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| * 1. **Hygiene and IPC included in education/training provided outside formal academic settings** | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | **⭘** Done  **⭘** In progress  **⭘** Not done | | **⭘** Done  **⭘** In progress  **⭘** Not done | |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | | | | | | | |

|  |  |
| --- | --- |
| 1. **Hygiene and infection prevention and control (IPC) measures are planned outside health settings** | ☑=Y |
| * 1. **Promotion of personal hygiene by social mobilization and behavioural change activities at home, at work and in social settings** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Prevention of infections in humans transmitted through sex or drug injection** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Provision of safe, sufficient drinking-water and adequate sanitation** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Strengthening of vaccination programmes to reduce the burden of infectious diseases** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Promotion of good hygiene practices along the food chain** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Good practices in place in animal health, welfare and production including vaccination** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Good practices in place in the plant production** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Good practices in place in the environment sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

**GAP Strategic Objective 4.** Optimize the use of antimicrobial agents in human and animal health

|  |  |
| --- | --- |
| 1. **Effective, enforceable regulation and governance are planned for licensing, distribution, and quality assurance of antimicrobial agents in human, animals, and plants** | ☑=Y |
| * 1. **There is a national human drug regulatory authority** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **There is a national animal drug regulatory authority** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **There are regulations in place for antimicrobial agents used in the plant sector** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Marketing authorization is given following international standards and guidelines to ensure that antimicrobial agents are quality assured, safe and effective** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Mechanisms or requirements are in place for detecting and combating counterfeit antimicrobial agents** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Promotional practices by industry are regulated and controlled** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **There is a quality management system for the antimicrobial agents supply chain** (e.g. for storage, transportation, expiry date) | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **There is a regulatory framework for preservation of new antimicrobial agents** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Economic incentives that encourage inappropriate use of antimicrobial agents are being identified and addressed in all sectors** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Economic incentives to optimize use of antimicrobial agents are being introduced in all sectors** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **Purchasing and prescribing of antimicrobial agents guided and supported by** | ☑=Y |
| * 1. **A national essential medicine list** guided by the WHO Model Lists of Essential Medicines | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Institutional essential medicine lists** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Reimbursement lists for human health** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Standard treatment guidelines for use of antimicrobial agents in humans** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Standard treatment guidelines for use of antimicrobial agents in animals** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Standard treatment guidelines for use of antimicrobial agents in plants** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Medical or veterinary supervision** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Standard treatment recommendations are developed for animals** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Standard treatment recommendations are developed for plants** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Policies that promote the prudent and responsible use of antimicrobial agents based on existing intergovernmental standards and guidelines** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **Policies on use of antimicrobial agents in animals and plants prepared, including** | ☑=Y |
| * 1. **Policies on the use of critically important antimicrobials** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Policies on phasing out use of antimicrobials for animal growth promotion and crop protection in the absence of risk analyses** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Policies on reduction in nontherapeutic use of antimicrobial agents in animal health** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

|  |  |
| --- | --- |
| 1. **Antimicrobial stewardship programmes set up for human health at national and local levels, including** | ☑=Y |
| * 1. **A formal multidisciplinary organizational structure responsible for antimicrobial stewardship** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Qualified human resources** An antimicrobial stewardship team including an antibiotic adviser or leader, an antimicrobial pharmacist, IPC professional, microbiologist | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Facility-specific treatment recommendations** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Review of appropriateness of antimicrobial agents 48–72 h after administration (post-prescription review)** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Direct communication of the results of audits and reviews to all sectors using antimicrobial agents** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

**GAP Strategic Objective 5.** Develop the economic case for sustainable investment to take into account the requirements of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions.

|  |  |
| --- | --- |
| 1. **An economic case for sustainable investment in new medicines, diagnostic tools, vaccines and other preventions and/or interventions prepared.** | ☑=Y |
| * 1. **The investment required for implementation of the national action plan has been assessed, and plans to secure and use the required financing have been prepared** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Participation in international collaboration, based on fair and equitable benefit-sharing as mutually agreed, in the investigation of natural sources of biodiversity and bio-repositories as sources of new antimicrobial agents** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Strengthening existing and creating new public–private partnerships for encouraging research and developing new antimicrobial agents, vaccines and diagnostics** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| * 1. **Pilot testing of innovative ideas for financing research and development and for new market models to encourage investment and ensure access to new antimicrobial products** | **⭘** Done  **⭘** In progress  **⭘** Not done |
| Gaps and challenges (e.g. lack of funds, lack of human resources, insufficient political will)  General comments: | |

1. This is a non-exhaustive generic list that needs to be adapted to countries situations;. The listed institutes or their equivalents could be included when the tool is adapted in a specific country. Other institutes could be added as necessary to ensure that all key sectors and functions are represented. [↑](#footnote-ref-1)
2. This is a non-exhaustive generic list; the specialities listed and their equivalents need to be adapted to each country’s situation. Other specialities and technical areas could be added to ensure that all key sectors are represented and expertise is available. [↑](#footnote-ref-2)